View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
August 21, 2012

NanoViricides reports survival improvements of oral FluCide drug candidates

NanoViricides, a development stage company, has reported that oral administration of their FluCide anti-influenza drug led to survival improvements comparable to IV administration.

NanoViricides, a development stage company, has reported that oral administration of their FluCide anti-influenza drug led to survival improvements comparable to IV administration.

Two different anti-influenza drug candidates were tested in the oral vs IV comparison, and both showed similar results that indicated stronger oral effectiveness than oseltamivir (Tamiflu).

The study involved the highly lethal animal model used by NanoViricides in its influenza drug development programme.

NanoViricides CEO Dr Eugene Seymour said the results showed FluCide could be developed as an oral drug for out-patient influenza.

"Many drugs are commercialised as oral drugs even if the oral dose needed is as high as five times the injectable dose," Seymour said.

One of the FluCide drug candidates, enabled the animals to survive up to 347.4±4.6 hrs (14.5 days) when administered orally.

When given as an injectable, it allowed the animals to fight the lethal influenza infection for 376.8±7.5 hrs (15.7 days).

The alternative drug candidate, which has a different anti-viral ligand, resulted in the animals surviving for up to 301.3±5.2 hrs (12.6 days) when given orally, and for 349.0±3.9 hrs (14.5 days) when given as a tail-vein injection.

For comparison, untreated control animals died in 119.5±1 hrs (5 days), and oseltamivir (Tamiflu) treated animals died within just 181.7±4.6 hrs (7.6 days).

The survival data showed that oral and IV administration of FluCide was substantially superior to oseltamivir, with oral doses matching the effectiveness of the injectable form given at 0.3 times the oral dosage level. No adverse effects were reported.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU